Organic Chemical
Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer
prostate cancer; talazoparib; Talzenna; NICE; NHS; enzalutamide
Nxera Pharma Reports Positive Phase 3 Results for Daridorexant in South Korea Insomnia Trial
Nxera Pharma; daridorexant; Phase 3; insomnia; South Korea; QUVIVIQ
Teva Launches First Generic GLP-1 for Weight Loss Amid Ongoing Market Developments
generic GLP-1; Teva; liraglutide; Saxenda; FDA approval; weight loss drugs
Cityblock Health Appoints New CTO and Tech-Focused Board Members to Accelerate AI-Driven Care
Cityblock Health; CTO; Alberto Lopez Toledo; board members; AI; Medicaid
FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels
FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos
FDA Announces Flexible Manufacturing Approach for Cell and Gene Therapies on January 11, 2026
FDA; cell and gene therapies; CGT; manufacturing flexibility; CMC requirements; Marty Makary
Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia
Eisai; Nuvation Bio; taletrectinib; ROS1+ NSCLC; licensing agreement; lung cancer
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin; MIRACLE trial; Annamycin; WP1066; AML; clinical trials; 2026 milestones